Management’s guidance upgrade for FY19
13/01/20 -"Given the strong uptake of Cimzia (33% of sales) and Vimpat (25% of sales) across geographies in Q4 19, we have upgraded our revenue estimates for the forecast years. Combined with robust operational ..."
Pages
52
Language
English
Published on
13/01/20
You may also be interested by these reports :
28/01/20
Novozymes reported mixed Q4 19 numbers – missing on topline but beating bottomline estimates. Sales came in at DKK 3,731m, up 1% on an organic basis, ...
24/01/20
As results of a futility analysis indicate that palovarotene’s phase III trial could miss the primary endpoint, Ipsen has suspended the studies ...
24/01/20
Besides lowering our DCF and NAV, we have increased the discount on the peer-based valuations to factor in this disappointing news. Our target price ...
21/01/20
Lonza reported a mixed set of condensed 2019 figures, which were below our expectations (EBITDA: -5%) but broadly met consensus based on adjusted ...